With the advent of highly active anti-retroviral therapy (HAART), significant progress has been achieved in the control of viral replication and prolongation of AIDS-free survival in HIV infected individuals. However, current therapeutic modalities do not effectively target or eliminate latent viral reservoirs. As a result, virus often rebounds after cessation of therapy. Significant side effects and drug-resistance are common due to the necessity for long-term multidrug therapy. An ultimate goal for anti-HIV therapy should therefore be virological eradication, i.e., to cure HIV infection. To date, the feasibility of virologic eradication has only been demonstrated in one HIV-infected patient given an allogeneic hematopoietic cell transplant (HCT) from a CCR5delta32 homozygous donor. Although this is an important proof-of-concept study, the likelihood of using HLA-matched and CCR5delta32 homozygous donor as a general therapeutic approach is remote. The overall objective of this U19 application is to explore strategies to introduce specific modifications in host and proviral DNA to target and eliminate latent HIV reservoir. The goal of this Core is to provide comprehensive support for the proof-of-concept studies in non-human primate models. This goal will be achieved through the execution of the following Specific Aims: (1). To provide animal resources, animal husbandry, and biosafety containment facilities necessary for the study of primate lentivirus infection in a non-human primate model;(2) To provide technical and clinical support for the implementation of non-human primate study protocols in this U19 application;(3) To provide laboratory expertise and analytical support for the monitoring of SHIV infection in macaques;and (4) To provide scientific and administrative oversight for the conduct of non-human primate studies. This Core will interact with all Projects and Cores of this U19.

Public Health Relevance

Despite significant progress has been achieved against HIV/AIDS, a cure remains elusive. Significant side effects and drug-resistance are common due to long-term use of multidrug therapies. A key objective of this U19 application will be to explore strategies to eradicate HIV in infected individuals. The goal of this Core is to provide comprehensive support for the proof-of-concept studies for these strategies in non-human primate models.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI096111-03
Application #
8497607
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
3
Fiscal Year
2013
Total Cost
$1,264,865
Indirect Cost
$170,540
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Colonna, Lucrezia; Peterson, Christopher W; Schell, John B et al. (2018) Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation. Nat Commun 9:4438
Paul, Biswajit; Ibarra, Guillermo S Romano; Hubbard, Nicholas et al. (2018) Efficient Enrichment of Gene-Modified Primary T Cells via CCR5-Targeted Integration of Mutant Dihydrofolate Reductase. Mol Ther Methods Clin Dev 9:347-357
Dubé, Karine; Dee, Lynda; Evans, David et al. (2018) Perceptions of Equipoise, Risk-Benefit Ratios, and ""Otherwise Healthy Volunteers"" in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. J Empir Res Hum Res Ethics 13:3-17
Adair, Jennifer E; Kubek, Sara P; Kiem, Hans-Peter (2017) Hematopoietic Stem Cell Approaches to Cancer. Hematol Oncol Clin North Am 31:897-912
Reeves, Daniel B; Peterson, Christopher W; Kiem, Hans-Peter et al. (2017) Autologous Stem Cell Transplantation Disrupts Adaptive Immune Responses during Rebound Simian/Human Immunodeficiency Virus Viremia. J Virol 91:
Niyonzima, Nixon; Lambert, Abigail R; Werther, Rachel et al. (2017) Tuning DNA binding affinity and cleavage specificity of an engineered gene-targeting nuclease via surface display, flow cytometry and cellular analyses. Protein Eng Des Sel 30:503-522
Peterson, Christopher W; Benne, Clarisse; Polacino, Patricia et al. (2017) Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation. JCI Insight 2:e91230
Reeves, Daniel B; Duke, Elizabeth R; Hughes, Sean M et al. (2017) Anti-proliferative therapy for HIV cure: a compound interest approach. Sci Rep 7:4011
Dubé, Karine; Taylor, Jeff; Sylla, Laurie et al. (2017) 'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States. PLoS One 12:e0170112
Chiarelli, Peter A; Revia, Richard A; Stephen, Zachary R et al. (2017) Nanoparticle Biokinetics in Mice and Nonhuman Primates. ACS Nano 11:9514-9524

Showing the most recent 10 out of 56 publications